◎ Sugi Atlas

Atlas / Drug / Resveratrol

Resveratrol

drug
On this page

Also known as (e)-resveratrol3,5,4'-trihydroxy-trans-stilbeneBiofortCa 1201CuspidatinJotrolMelinjo resveratrol 20NSC-327430PolygoninResveratrol p 5Resveratrol(e)-formResvidaSrt 501mTrans-resveratrol4,3',5'-trihydroxystilbeneresveratrotrans-3,5,4'-trihydroxystilbene3',4,5'-trihydroxystilbene3,5,4'-trans-trihydroxystibene

Summary

Resveratrol (CHEMBL165) is an approved small-molecule quorum sensing inhibitor targeting PTGS2, PPARG, and TAS2R14; indicated across 39 conditions including metabolic syndrome x and chronic obstructive pulmonary disease.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • Targets: 3 (PTGS2, PPARG, TAS2R14)
  • Indications: 39 conditions
  • Clinical trials: 139
  • Chemistry: 228.24 Da · C14H12O3

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL165
NameResveratrol
TypeSmall molecule
Max phase3
FDA approvedyes
PubChem CID445154
ChEBICHEBI:45713
Molecular formulaC14H12O3
Molecular weight228.24
InChIKeyLUKBXSAWLPMMSZ-OWOJBTEDSA-N

SMILES: C1=CC(=CC=C1/C=C/C2=CC(=CC(=C2)O)O)O

IUPAC name: 5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol

ChEBI definition: A resveratrol in which the double bond has E configuration.

Pharmacological roles (ChEBI): antioxidant, phytoalexin, radical scavenger, quorum sensing inhibitor.

Other ChEBI roles (chemical / environmental): plant metabolite.

Also known as: (e)-resveratrol, 3,5,4’-trihydroxy-trans-stilbene, Biofort, Ca 1201, Cuspidatin, Jotrol, Melinjo resveratrol 20, NSC-327430, Polygonin, Resveratrol, Resveratrol p 5, Resveratrol(e)-form

Patent coverage: 25,199 distinct patent families (60,144 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
PTGS2COX-2Inhibition6.120%P35354
PPARGPeroxisome proliferator-activated receptor-γAntagonist5.852.6%P37231
TAS2R14TAS2R14Agonist4.520.1%Q9NYV8

Broader ChEMBL bioactivity targets: 91 (assay-derived). Sample: Nuclear factor erythroid 2-related factor 2, Myc proto-oncogene protein, Microtubule-associated protein tau, Lysine-specific demethylase 4E, Nuclear receptor ROR-gamma, Survival motor neuron protein, Prelamin-A/C, RecQ-like DNA helicase BLM, Inositol monophosphatase 1, 15-hydroxyprostaglandin dehydrogenase [NAD(+)].

Bioactivity

ChEMBL activities: 119 potent at pChembl ≥ 5 of 233 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
DPP49.22IC500.6nMCHEMBL_ACT_18662268
LMNA8.3Potency5nMCHEMBL_ACT_3628175
NQO27.27Kd54nMCHEMBL_ACT_13446519
P086597.23IC5058.88nMCHEMBL_ACT_12665974
NQO27.06Ki88nMCHEMBL_ACT_13446567
O027476.77Ki169nMCHEMBL_ACT_1419643
CYP1A16.64IC50230nMCHEMBL_ACT_25005360
PIK3CA6.6IC50250nMCHEMBL_ACT_14553315
P059796.42IC50380nMCHEMBL_ACT_1759901
NQO26.35IC50450nMCHEMBL_ACT_3110609
NQO26.35IC50450nMCHEMBL_ACT_3274536
MAOA6.35IC50449nMCHEMBL_ACT_7806805
TTR6.33Kd470nMCHEMBL_ACT_18091496
PIK3CB6.3IC50500nMCHEMBL_ACT_14553320
P059796.27IC50535nMCHEMBL_ACT_16465904
P059796.27IC50535nMCHEMBL_ACT_1888137
CYP3A46.22IC50600nMCHEMBL_ACT_7804732
PTGS16.2IC50625nMCHEMBL_ACT_7804716
Q6RI866.12IC50750nMCHEMBL_ACT_16433392
TRPA16.12IC50750nMCHEMBL_ACT_18105526
CYP1B16.12Ki750nMCHEMBL_ACT_18948702
PTGS26.12IC50750nMCHEMBL_ACT_3362248
ESR16.11Ki785nMCHEMBL_ACT_1419644
CYP1B16.1Ki800nMCHEMBL_ACT_18157527
NQO26.1IC50790nMCHEMBL_ACT_29197581
CA96.09Ki810nMCHEMBL_ACT_3426903
PTGS16.08IC50830nMCHEMBL_ACT_2507715
CA146.08Ki830nMCHEMBL_ACT_3426924
NQO26.05IC50900nMCHEMBL_ACT_19082051
NQO26.04IC50913nMCHEMBL_ACT_16492598

Target pathways

Aggregated over 3 target gene(s): PTGS2, PPARG, TAS2R14.

Top Reactome pathways

25 total, by targets touching each:

PathwayTargetsGenes
Signal Transduction1TAS2R14
PPARA activates gene expression1PPARG
Synthesis of 15-eicosatetraenoic acid derivatives1PTGS2
Synthesis of Prostaglandins (PG) and Thromboxanes (TX)1PTGS2
Signaling by GPCR1TAS2R14
Transcriptional regulation of white adipocyte differentiation1PPARG
Nuclear Receptor transcription pathway1PPARG
GPCR downstream signalling1TAS2R14
SUMOylation of intracellular receptors1PPARG
G alpha (i) signalling events1TAS2R14
Class C/3 (Metabotropic glutamate/pheromone receptors)1TAS2R14
GPCR ligand binding1TAS2R14
Interleukin-10 signaling1PTGS2
Interleukin-4 and Interleukin-13 signaling1PTGS2
Regulation of PTEN gene transcription1PPARG
Biosynthesis of DHA-derived SPMs1PTGS2
Biosynthesis of EPA-derived SPMs1PTGS2
MECP2 regulates transcription factors1PPARG
Biosynthesis of DPAn-3 SPMs1PTGS2
Biosynthesis of electrophilic ω-3 PUFA oxo-derivatives1PTGS2
Sensory Perception1TAS2R14
Sensory perception of taste1TAS2R14
Sensory perception of sweet, bitter, and umami (glutamate) taste1TAS2R14
MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis1PPARG
Transcriptional regulation of brown and beige adipocyte differentiation by EBF21PPARG

Dominant GO biological processes

GO termTargets
regulation of blood pressure2
brown fat cell differentiation2
cellular response to hypoxia2
fatty acid metabolic process2
G protein-coupled receptor signaling pathway2
prostaglandin biosynthetic process1
response to oxidative stress1
embryo implantation1
response to nematode1
response to selenium ion1
positive regulation of vascular endothelial growth factor production1
cyclooxygenase pathway1
lipoxygenase pathway1
positive regulation of prostaglandin biosynthetic process1
positive regulation of fever generation1

Indications & clinical

Indications

39 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
metabolic syndrome X3MONDO:0011565EFO:0000195
chronic obstructive pulmonary disease3MONDO:0005002EFO:0000341
dilated cardiomyopathy3MONDO:0005021EFO:0000407
infertility disorder3MONDO:0005047EFO:0000545
chronic kidney disease3MONDO:0005300EFO:0003884
seasonal allergic rhinitis3MONDO:0005324EFO:0003956
peripheral arterial disease3MONDO:0005386EFO:0004265
Huntington disease3MONDO:0007739MONDO:0007739
osteoarthritis, knee3MONDO:0005416EFO:0004616
paraplegia2MONDO:0003757HP:0001258
metabolic dysfunction-associated steatotic liver disease2MONDO:0013209EFO:0003095
follicular lymphoma2MONDO:0018906MONDO:0018906
severe acute respiratory syndrome2MONDO:0005091EFO:0000694
polycystic ovary syndrome2MONDO:0008487EFO:0000660
age-related macular degeneration2MONDO:0005150EFO:0001365
Alzheimer disease2MONDO:0004975MONDO:0004975
type 2 diabetes mellitus2MONDO:0005148MONDO:0005148
lymphangioleiomyomatosis2MONDO:0011705MONDO:0011705
Friedreich ataxia2MONDO:0100339MONDO:0100339
diabetic neuropathy2MONDO:0006626EFO:1000783
cardiovascular disorder1MONDO:0004995EFO:0000319
neoplasm1MONDO:0005070EFO:0000616
colorectal adenocarcinoma1MONDO:0005008EFO:0000365
hypertensive disorder1MONDO:0005044EFO:0000537
rectal cancer1MONDO:0006519EFO:1000657
colonic neoplasm1MONDO:0005401MONDO:0021063
Parkinson disease1MONDO:0005180MONDO:0005180
diabetic kidney disease0MONDO:0005016EFO:0000401
type 1 diabetes mellitus0MONDO:0005147MONDO:0005147
cystic fibrosis0MONDO:0009061MONDO:0009061

9 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 139.

Phase distribution

PhaseTrials
Not specified76
PHASE223
PHASE113
PHASE310
PHASE1/PHASE25
PHASE44
PHASE2/PHASE34
EARLY_PHASE14

Top trials by phase / activity

NCTPhaseStatusTitle
NCT01997762PHASE4UNKNOWNCan Resveratrol Improve Insulin Sensitivity and Preserve Beta Cell Function Following Gestational Diabetes?
NCT02475564PHASE4COMPLETEDResveratrol for Pain Due to Endometriosis
NCT02947932PHASE4UNKNOWNOral Resveratrol to Prevent Post-ERCP Pancreatitis
NCT03384329PHASE4COMPLETEDEfficacy of Resveratrol in Depression
NCT06882564PHASE3RECRUITINGEfficacy of Resveratrol Containing Mouthwash in Reducing Halitosis Related Porphyrymonas Gingivalis.
NCT00996229PHASE3UNKNOWNEffects of Dietary Interventions on the Aging Brain
NCT01219244PHASE2/PHASE3COMPLETEDEffects of Dietary Interventions on the Brain in Mild Cognitive Impairment (MCI)
NCT01492114PHASE3COMPLETEDAnti-inflammatory and Antioxidant Effects of Resveratrol on Healthy Adults.
NCT01914081PHASE3UNKNOWNResveratrol: A Potential Anti- Remodeling Agent in Heart Failure, From Bench to Bedside
NCT02030977PHASE2/PHASE3COMPLETEDThe Effects of Resveratrol Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Steatohepatitis
NCT02216552PHASE2/PHASE3COMPLETEDResveratrol for the Treatment of Non Alcoholic Fatty Liver Disease and Insulin Resistance in Overweight Adolescents
NCT02244879PHASE3COMPLETEDEffects of Resveratrol on Inflammation in Type 2 Diabetic Patients
NCT02433925PHASE3COMPLETEDResveratrol’s Effects on Inflammation and Oxidative Stress in Chronic Kidney Disease
NCT02905799PHASE3COMPLETEDResveratrol in Knee Osteoarthritis
NCT03446625PHASE3COMPLETEDResveratrol as a Preventive Treatment of OHSS
NCT03683108PHASE3COMPLETEDEfficacy and Safety of Resveratrol and Carbossimetyl Beta Glucan in Treatment of Upper Airways Disease in Infancy
NCT03743636PHASE3COMPLETEDNicotinamide Riboside With and Without Resveratrol to Improve Functioning in Peripheral Artery Disease
NCT07332819PHASE2/PHASE3COMPLETEDResveratol in Diabetic Nephropathy
NCT07592767PHASE2NOT_YET_RECRUITINGRESvEraTrol in Parkinson’s Disease (RESET)
NCT00654667PHASE2WITHDRAWNMechanisms of Metabolic Regulation of Resveratrol on Humans With Metabolic Syndrome
NCT01321151PHASE1/PHASE2COMPLETEDUse of Resveratrol to Decrease Acute Secondary Brain Injury Following Sports-Related Concussions in Boxers
NCT01339884PHASE1/PHASE2COMPLETEDA Study of Resveratrol as Treatment for Friedreich Ataxia
NCT01354977PHASE2COMPLETEDEffect of Resveratrol on Age-related Insulin Resistance and Inflammation in Humans
NCT01451918PHASE2COMPLETEDRegulation of Intestinal and Hepatic Lipoprotein Secretion by Resveratrol
NCT01504854PHASE2COMPLETEDResveratrol for Alzheimer’s Disease
NCT01564381PHASE1/PHASE2COMPLETEDEffects of Resveratrol Supplements on Vascular Health in Postmenopausal Women
NCT01615445PHASE2COMPLETEDResveratrol Supplementation on Exercise in Healthy Sedentary Adults
NCT01842399PHASE1/PHASE2TERMINATEDResveratrol and Cardiovascular Health in the Elderly
NCT02062190PHASE2COMPLETEDResveratrol, Cardiovascular Risk Markers And Cognitive Performance In Patients With Schizophrenia
NCT02114892PHASE2COMPLETEDEffect of Resveratrol Administration on Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion
NCT02123121PHASE2COMPLETEDResveratrol to Enhance Vitality and Vigor in Elders
NCT02247596PHASE2COMPLETEDEffects of High-Dose Resveratrol in Non-Diabetic Obese Males
NCT02261844PHASE1/PHASE2WITHDRAWNResveratrol and Human Hepatocyte Function in Cancer
NCT02314208PHASE2COMPLETEDTherapeutic Metabolic Intervention in Patients With Spastic Paraplegia SPG5
NCT02409537PHASE2COMPLETEDEffects of Dietary Antioxidants to Prevent Cardiovascular Disease
NCT02523274PHASE2COMPLETEDResveratrol and Exercise to Treat Functional Limitations in Late Life
NCT02549924PHASE2TERMINATEDEffect of Administration of Resveratrol on Glycemic Variability in Individuals With Type 2 Diabetes Mellitus
NCT03253913PHASE2COMPLETEDResveratrol and Sirolimus in Lymphangioleiomyomatosis Trial
NCT03525379PHASE2COMPLETEDEvaluating the Clinical Efficacy of Resveratrol in Improving Metabolic and Skeletal Muscle Function in Patients With Heart Failure
NCT03665740PHASE2UNKNOWNMultimodal Investigation of the Neuroprotective Effects of Resveratrol (MINER)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

268 molecules share ≥1 primary target. Top 60 by shared-target count:

MoleculeSourceStatusShared targets
FulvestrantChEMBL + PubChemPhase 4 (approved)PPARG, PTGS2
CANDESARTAN CILEXETILChEMBLPhase 4 (approved)PPARG, PTGS2
CANNABIDIOLChEMBLPhase 4 (approved)PPARG, PTGS2
INDOMETHACINChEMBLPhase 4 (approved)PPARG, PTGS2
LASOFOXIFENEChEMBLPhase 4 (approved)PPARG, PTGS2
LEVOTHYROXINEChEMBLPhase 4 (approved)PPARG, PTGS2
LUMIRACOXIBChEMBLPhase 4 (approved)PPARG, PTGS2
MASOPROCOLChEMBLPhase 4 (approved)PPARG, PTGS2
SULINDACChEMBLPhase 4 (approved)PPARG, PTGS2
TIPRANAVIRChEMBLPhase 4 (approved)PPARG, PTGS2
TROGLITAZONEChEMBLPhase 4 (approved)PPARG, PTGS2
QUERCETINChEMBLPhase 3PPARG, PTGS2
FLUFENAMIC ACIDChEMBLPhase 2PTGS2, TAS2R14
AfatinibPubChemApprovedPPARG, PTGS2
ApixabanPubChemApprovedPPARG, PTGS2
BinimetinibPubChemApprovedPPARG, PTGS2
chenodiolPubChemApprovedPPARG, PTGS2
ImipenemPubChemApprovedPPARG, PTGS2
FIDAXOMICINChEMBL + PubChemPhase 4 (approved)PTGS2
3,3’,4’,5-TETRACHLOROSALICYLANILIDEChEMBLPhase 4 (approved)PTGS2
ABEMACICLIBChEMBLPhase 4 (approved)PTGS2
ACALABRUTINIBChEMBLPhase 4 (approved)PTGS2
ACEMETACINChEMBLPhase 4 (approved)PTGS2
ACETOPHENAZINEChEMBLPhase 4 (approved)PTGS2
ACETYLCYSTEINEChEMBLPhase 4 (approved)PTGS2
ACRIVASTINEChEMBLPhase 4 (approved)PTGS2
AMODIAQUINEChEMBLPhase 4 (approved)PTGS2
AMPHOTERICIN BChEMBLPhase 4 (approved)PTGS2
AMSACRINEChEMBLPhase 4 (approved)PTGS2
ANISINDIONEChEMBLPhase 4 (approved)PTGS2
APOMORPHINEChEMBLPhase 4 (approved)PTGS2
ARFORMOTEROLChEMBLPhase 4 (approved)PTGS2
ASPIRINChEMBLPhase 4 (approved)PTGS2
BAZEDOXIFENEChEMBLPhase 4 (approved)PTGS2
BENZBROMARONEChEMBLPhase 4 (approved)PPARG
BENZQUINAMIDEChEMBLPhase 4 (approved)PTGS2
BEPRIDILChEMBLPhase 4 (approved)PTGS2
BEXAROTENEChEMBLPhase 4 (approved)PPARG
BIPERIDENChEMBLPhase 4 (approved)PTGS2
BROMFENACChEMBLPhase 4 (approved)PTGS2
CALCIPOTRIENEChEMBLPhase 4 (approved)PTGS2
CALCITRIOLChEMBLPhase 4 (approved)PTGS2
CAPSAICINChEMBLPhase 4 (approved)PTGS2
CAPTOPRILChEMBLPhase 4 (approved)PTGS2
CARPROFENChEMBLPhase 4 (approved)PTGS2
CARVEDILOLChEMBLPhase 4 (approved)PPARG
CEFAMANDOLEChEMBLPhase 4 (approved)PPARG
CEFAZOLINChEMBLPhase 4 (approved)PTGS2
CEFOTAXIMEChEMBLPhase 4 (approved)PPARG
CEFOXITINChEMBLPhase 4 (approved)PPARG
CEFTAZIDIMEChEMBLPhase 4 (approved)PPARG
CEFTIZOXIMEChEMBLPhase 4 (approved)PTGS2
CEFTRIAXONEChEMBLPhase 4 (approved)PPARG
CELECOXIBChEMBLPhase 4 (approved)PTGS2
CEPHRADINEChEMBLPhase 4 (approved)PTGS2
CIANIDANOLChEMBLPhase 4 (approved)PTGS2
CLOBETASOL PROPIONATEChEMBLPhase 4 (approved)PPARG
CLOTRIMAZOLEChEMBLPhase 4 (approved)PTGS2
CRIZOTINIBChEMBLPhase 4 (approved)PTGS2
DAUNORUBICINChEMBLPhase 4 (approved)PTGS2

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot